Myeloma bone disease: Recent advances in biology, diagnosis, and treatment

Oncologist

Volumn 14, Issue 3, 2009, Pages 276-283

  Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biochemical markers; Bone; DKK 1; ICTP; MIP 1; Multiple myeloma; Osteoblast; Osteoclast; Osteoprotegerin; RANKL

Indexed keywords

BHQ 880; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DENOSUMAB; DICKKOPF 1 PROTEIN; DICKKOPF 1 PROTEIN ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; POLY(METHYL METHACRYLATE); PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ARTICLE; BONE DESTRUCTION; BONE DISEASE; BONE PAIN; BONE TURNOVER; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; COMPRESSION FRACTURE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG INDICATION; FRACTURE; HUMAN; HYPERCALCEMIA; INHIBITION KINETICS; MOUTH HYGIENE; MULTIPLE MYELOMA; MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PATHOGENESIS; PERCUTANEOUS VERTEBROPLASTY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR;

HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS;

EID: 63849093676     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0003     Document Type: Article

References (92)

1. Ludwig H. Advances in biology and treatment of multiple myeloma. Ann Oncol 2005;16(suppl 2):ii106-ii12.
2. Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol 2004;125:24-30.
3. Ludwig H, Zojer N. Supportive care in multiple myeloma. Best Pract Res Clin Haematol 2007;20:817-835.
4. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121:749-757.
5. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
6. Cocks K, Cohen D, Wisff F et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ- MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43:1670-1678.
7. Jakob C, Sterz J, Liebisch P et al. Incorporation of the bone marker car- boxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008;22:1767-1772.
8. Melton LJ 3rd, Kyle RA, Achenbach SJ et al. Fracture risk with multiple myeloma: A population-based study. J Bone Miner Res 2005;20:487-493.
9. Bruce NJ, McCloskey EV, Kanis JA et al. Economic impact of using clodronate in the management of patients withmultiple myeloma. Br J Haematol 1999;104:358-364.
10. Bataille R, Chappard D, Marcelli C et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991;88:62-66.
11. Yaccoby S, Wezeman MJ, Henderson A et al. Cancer and the microenvi-ronment: Myeloma-osteoclast interactions as a model. Cancer Res 2004; 64:2016-2023.
12. Valentin-Opran A, Charhon SA, Meunier PJ et al. Quantitative histology of myeloma-induced bone changes. Br J Haematol 1982;52:601-610.
13. Hecht M, von Metzler I, Sack K et al. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp Cell Res 2008;314:1082-1093.
14. Mundy GR, Raisz LG, Cooper RA et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974;291:1041-1046.
15. Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179.
16. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176. 17 Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89: 309 -319.
17. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclas-togenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
18. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260 -1268.
19. HofbauerLC, Khosla S, Dunstan CR et al. The roles ofosteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
20. Pearse RN, Sordillo EM, Yaccoby S et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad SciUSA 2001;98:11581-11586.
21. Giuliani N, Bataille R, Mancini C et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-3533.
22. Sezer O, Heider U, Zavrski I et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-2098.
23. Croucher PI, Shipman CM, Lippitt J et al. Osteoprotegerin inhibits the development ofosteolytic bone disease in multiple myeloma. Blood 2001;98: 3534-3540.
24. Heider U, Langelotz C, Jakob C et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436-1440.
25. Farrugia AN, Atkins GJ, To LB et al. Receptor activator of nuclear factor- kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-5445.
26. Qiang YW, Chen Y, Stephens O et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteo- blasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008;112:196-207.
27. Standal T, Seidel C, Hjertner 0 et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100:3002-3007.
28. Terpos E, Szydlo R, Apperley JF et al. Soluble receptor activator ofnuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index. Blood 2003;102:1064-1069.
29. Choi SJ, Cruz JC, Craig F et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-675.
30. Choi SJ, Oba Y, Gazitt Y et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833-1841.
31. Abe M, Hiura K, Wilde J et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195-2202.
32. Oyajobi BO, Franchin G, Williams PJ et al. Dual effects of macrophage inflammatory protein-1α on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-319.
33. Lentzsch S, Gries M, Janz M et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating sur
34. vival and proliferation in multiple myeloma (MM) cells. Blood 2003;101: 3568-3573.
35. Lentzsch S, Ehrlich LA, Roodman GD. Pathophysiology of multiple myeloma bone disease. Hematol Oncol Clin North Am 2007;21:1035-1049.
36. Zannettino AC, Farrugia AN, Kortesidis A et al. Elevated serum levels of stromal-derived factor-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005;65:1700-1709.
37. Silvestris F, Ciavarella S, De Matteo M et al. Bone-resorbing cells in multiple myeloma: Osteoclasts, myeloma cell polykaryons, or both? The Oncologist 2009;14:264-275.
38. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
39. Evans CE, Ward C, Rathour L et al. Myeloma affects both the growth and function of human osteoblast-like cells. Clin Exp Metastasis 1992; 10:33-38.
40. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling inosteoblasts and bone diseases. Gene 2004;341:19-39.
41. Gong Y, Slee RB, Fukai N et al.; Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-523.
42. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-2634.
43. Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-2494.
44. Politou MC, Heath DJ, Rahemtulla A et al. Serum concentrations of Dick- kopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119:1728-1731.
45. Kaiser M, Mieth M, Liebisch P et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80:490-494.
46. Heider U, Kaiser M, Mieth M et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009;82:31-38.
47. Qiang YW, Barlogie B, Rudikoff S et al. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008;42:669-680.
48. Yaccoby S, Ling W, ZhanF et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007;109:2106-2111.
49. Oshima T, Abe M, Asano J et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005;106:3160-3165.
50. Hecht M, Heider U, Kaiser M et al. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 2007;138:446-458.
51. Barillé S, Collette M, Bataille R et al. Myeloma cells upregulate interleu- kin-6 secretion in osteoblastic cells through cell-to-cell contact but down-regulate osteocalcin. Blood 1995;86:3151-3159.
52. Ehrlich LA, Chung HY, Ghobrial I et al. IL-3 is a potential inhibitor of osteoblastdifferentiationin multiple myeloma. Blood 2005;106:1407-1414.
53. Giuliani N, Colla S, Morandi F et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteo-blast formation and differentiation. Blood 2005;106:2472-2483.
54. Yaccoby S, WezemanMJ, Zangari M et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006;91:192-199.
55. Silvestris F, Cafforio P, Tucci M et al. Upregulation of osteoblast apoptosis by malignant plasma cells: A role in myeloma bone disease. Br J Haematol 2003;122:39-52.
56. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23: 10 -24.
57. Horger M, Claussen CD, Bross-Bach U et al. Whole-body low-dose mul- tidetector row-CT in the diagnosis of multiple myeloma: An alternative to conventional radiography. Eur J Radiol 2005;54:289-297.
58. Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997;90:2127-2147.
59. Mulligan ME, Badros AZ. PET/CT and MR imaging in myeloma. Skeletal Radiol 2007;36:5-16.
60. Moulopoulos LA, Dimopoulos MA, Smith TL et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 1995;13:251-256.
61. WalkerR, BarlogieB, HaesslerJetal. Magneticresonanceimaging inmul- tiple myeloma: Diagnostic and clinical implications. J Clin Oncol 2007;25: 1121-1128.
62. Heider U, Fleissner C, Zavrski I et al. Bone markers in multiple myeloma. Eur J Cancer 2006;42:1544-1553.
63. Coleman RE. Bisphosphonates: Clinical experience. The Oncologist 2004; 9(suppl 4):14-27.
64. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-493.
65. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
66. Lahtinen R, Laakso M, Palva I et al. Randomised, placebo-controlled mul- ticentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992;340:1049-1052.
67. McCloskey EV, Dunn JA, Kanis JA et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001;113:1035-1043.
68. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558 -567.
69. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
70. Ruggiero SL, Mehrotra B, Rosenberg TJ et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
71. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005;23:8580-8587.
72. Kyle RA, Yee GC, Somerfield MR et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphos- phonates in multiple myeloma. J Clin Oncol 2007;25:2464-2472.
73. Terpos E, Sezer O, Croucher P et al. Guidance for the use of bisphospho-
74. nates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009 (in press).
75. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw(ONJ) after implementation of preventive measures inpatients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009;20:117-120.
76. Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20:137-145.
77. von Metzler I, Krebbel H, Hecht M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21:2025-2034.
78. Zavrski I, Kleeberg L, Kaiser M et al. Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des 2007;13:471-485.
79. Jakob C, Egerer K, Liebisch P et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007;109:2100-2105.
80. Sterz J, von Metzler I, Hahne JC et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008;17:879-895.
81. Zavrski I, Krebbel H, Wildemann B et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 2005;333:200-205.
82. Boissy P, Andersen TL, Lund T et al. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk Res 2008;32:1661-1668.
83. vonMetzlerI, KrebbelH, KuckelkornUetal. Curcumindiminishes human osteoclastogenesis by inhibition of the signalosome-associated I-kB kinase. J Cancer Res Clin Oncol 2009;135:173-179.
84. Zangari M, Esseltine D, Lee CK et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005;131:71-73.
85. Heider U, Kaiser M, Müller C et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006;77:233-238.
86. Giuliani N, Morandi F, Tagliaferri S et al. The proteasome inhibitor bort- ezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334-338.
87. Mukherjee S, Raje N, Schoonmaker JA et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008;118:491-504.
88. Terpos E, Sezer O, Croucher P et al. Myeloma bone disease and proteasome inhibition therapies. Blood 2007;110:1098-1104.
89. Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007;21:1875-1884.
90. Fulciniti M, Tassone P, Hideshima T et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic for multiple myeloma. Blood 2007;110(suppl 1): 169a.
91. Body JJ, Facon T, Coleman RE et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;12:1221-1228.
92. Hussein MA, Vrionis FD, Allison R et al. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 2008;22:1479-1484.